288PDPERNETTA: A non-comparative randomized open label phase II trial of pertuzumab (P) + trastuzumab (T) with or without chemotherapy both followed by T-DM1 in case of progression, in patients with HER2-positive metastatic breast cancer (MBC): (SAKK 22/10 / UNICANCER UC-0140/1207). (23rd October 2018) - Huober, J; Weder, P; Veyret, C; Thürlimann, B; Xyrafas, A; Vanlemmens, L; Guiu, S; Brain, E; Grenier, J; Dalenc, F; Levy, C; Savoye, A M; et al.